Erasca, Inc.
Small-molecule therapeutics targeting the RAS/MAPK signaling pathway in cancer
New patent ·
- Sector
- Biotech
- Headquarters
- San Diego, CA
- Founded
- 2018
- Latest Form D
- $125M, Apr 2020
- Total capital
- $167M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $167M
- 2 Form D · last Apr 2020
- 78 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 36 pending · first 2023
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$125M
- Private capital raisedForm D · SEC · 1st filing$41.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alexander W. CasdinDirectorNamed in SEC Form D filings
- Gary E. Yeung, CFAExecutive OfficerNamed in SEC Form D filings
- James A. Bristol, Ph.D.DirectorNamed in SEC Form D filings
- Jonathan Lim, M.D.Executive Officer, DirectorNamed in SEC Form D filings
- Pratik S. Multani, M.D.DirectorNamed in SEC Form D filings
- Valerie S. Harding-StartDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 40- New patentAntibodies Against Egfr And Their UsesUSPTOUS 12,760,111
- PendingRas And PRMT5 Inhibitors Combination TherapyUSPTOApplication 19664682
- PendingRaf Inhibitor And Kras G12C Inhibitor Combination TherapyUSPTOApplication 19145652
Show all 40 patent records
- Antibodies Against Egfr And Their UsesOct 13, 2026 · US 12,760,111Granted
- Ras And PRMT5 Inhibitors Combination TherapySep 17, 2026 · Application 19664682Pending
- Raf Inhibitor And Kras G12C Inhibitor Combination TherapyJul 30, 2026 · Application 19145652Pending
- POLYMORPHIC FORMS OF (S)-N-(3-BROMO-2-FLUOROPHENYL)-7-((4-METHYLPIPERAZIN-1-YL)METHYL)-7,8-DIHYDRO-[1,4]DIOXINO[2,3-g]QUINAZOLIN-4-AMINE AS EGFR INHIBITORSFeb 10, 2026 · US 12,545,686Granted
- Tricyclic Pyridones And PyrimidonesOct 9, 2025 · Application 18860263Pending
- Combination Therapies For The Treatment Of CancerJun 19, 2025 · Application 18256091Pending
- Thiophene ULK1/2 Inhibitors And Their Use ThereofMay 8, 2025 · Application 18708947Pending
- Jak Inhibitor With ERK1/2 And/or SHP2 Inhibitors Combination TherapyApr 17, 2025 · Application 18692508Pending
- Antibodies Against Egfr And Their UsesFeb 6, 2025 · Application 18844785Pending
- Uses Of Tri-substituted Heteroaryl Derivatives As Src HOMOLOGY-2 Phosphatase InhibitorsDec 19, 2024 · Application 18698492Pending
- Tricyclic Pyridones And PyrimidonesDec 10, 2024 · US 12,162,893Granted
- Antibodies Against Egfr And Their UsesNov 21, 2024 · Application 18573339Pending
- Amide And Urea-containing Tricyclic Kras InhibitorsNov 21, 2024 · Application 18571138Pending
- ERK1/2 And Egfr Inhibitors Combination TherapySep 19, 2024 · Application 18570830Pending
- ERK1/2 And SHP2 Inhibitors Combination TherapySep 12, 2024 · Application 18572404Pending
- Kras Inhibitor ConjugatesSep 5, 2024 · Application 18570993Pending
- SHP2 And CDK4/6 Inhibitors Combination Therapies For The Treatment Of CancerSep 5, 2024 · Application 18572412Pending
- ERK1/2 Or SHP2 Inhibitors And FLT3 Inhibitors Combination TherapyAug 29, 2024 · Application 18570831Pending
- ERK1/2 And Kras G12C Inhibitors Combination TherapyAug 29, 2024 · Application 18572399Pending
- Uses Of Heterocyclic Inhibitors Of ERK1/2Jun 27, 2024 · Application 18555071Pending
- Compositions And Methods For Treating CancerFeb 22, 2024 · Application 18027313Pending
- Combination Therapies For The Treatment Of CancerFeb 22, 2024 · Application 18256090Pending
- Combination Therapies For The Treatment Of CancerFeb 15, 2024 · Application 18256089Pending
- Tricyclic Pyridones And PyrimidonesDec 19, 2023 · US 11,845,761Granted
- Tricyclic Pyridones And PyrimidonesJun 29, 2023 · Application 17807464Pending
- Tricyclic Pyridones And PyrimidonesApr 6, 2023 · Application 17556498Pending
- Pyrrolidine-fused HeterocyclesSep 23, 2021 · Application 17187541Pending
- Ras And CTLA-4 Inhibitors Combination TherapyApplication 63750554Pending
- Method Of Treatment Of Double Wt MelanomaApplication 63761528Pending
- Ras And Egfr Inhibitors Combination TherapyApplication 63721084Pending
- Raf Inhibitor And ERK1/2 And/or SHP2 Inhibitor Combination TherapyApplication 19145654Pending
- Ras And CTLA-4 Inhibitors Combination TherapyApplication PCTUS2026012663Pending
- Ras Inhibitors Combination TherapyApplication 63721094Pending
- Kras InhibitorsApplication 19157251Pending
- Method Of Treatment Of Double Wt MelanomaApplication PCTUS2026015946Pending
- Kras InhibitorsApplication PCTUS2024061389Pending
- Kras InhibitorsApplication PCTUS2025011114Pending
- Ras And PRMT5 Inhibitors Combination TherapyApplication PCTUS2025042860Pending
- Ras And Egfr Inhibitors Combination TherapyApplication PCTUS2025055396Pending
- SHP2 And Egfr Inhibitors For The Treatment Of ChordomaApplication 63637830Pending
Related companies, and why
- TRIANA BiomedicinesSimilar federal contract value in Biotech · null in contracts
- Monocacy Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- Fulcrum TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Skye BioscienceSimilar federal contract value in Biotech · null in contracts
- LIGHT SWITCH BIO, LLCSimilar federal contract value in Biotech · null in contracts
- Artiva BiotherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .